RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
General Atlantic, a global growth equity firm, invested $150 million in Hong Kong Asia Medical Holding. Asia Holding provides cardiovascular healthcare services and operates hospitals under the name Asia Heart. Currently, the company operates two hospitals in Wuhan and Xinjiang. It also co-manages four heart centers including a new one in Hong Kong and another recently acquired center in Japan. The company will also open a second branch in Wuhan in November. Founded in 1999, Asia Heart offers heart surgeries and other cardiovascular services.
Source: China Biotoday
